Revenue increased 50.3% year-over-year to $74.1 million in Q3 2026Clinical revenue increased 20.3% sequentially in Q3 2026 vs Q2 2026Q3 2026 net loss from continuing operations of $(7.6) million or (10.3)% of revenueAdjusted EBITDA(1) of $9.6 million in Q3 2026; Adjusted EBITDA margin of 13.0%Cash flow from operating activities was $9.5 million in Q3 2026; Free Cash Flow(1) was $8.6 million in Q3 2026Announced $20 million share repurchase authorization; will be deployed along with continued M&A strategy exe ...